Table 3 Median (range) of serological parameters and cell subsets of patients treated with MMF or CYC compared to controls
Madian (range) serological parameters and cell subsets | MMF | CYC | Controls |
|---|---|---|---|
(number = 25) | (number = 20) | (number = 22) | |
anti-dsDNA (U/ml) | 38 (0 to 927) | 38 (0 to 7536) | 28 (0 to 963) |
C3c (g/L) | 0.8 (0.4 to 1.1) | 0.8 (0.5 to 1.5) | 0.8 (0.2 to 1.4) |
FLCkappa (mg/L) | 19.0 (9.6 to 52.0)aab | 34.9 (1.6 to 246.0)aa | 26.7 (9.2 to 148.0)b |
FLClambda (mg/L) | 21.8 (10.0 to 47.8)b | 30.2 (4.1 to 153.0) | 32.8 (12.9 to 99.3)b |
IgG (g/L | 10.5 (4.9 to 16.3)b | 11.8 (3.8 to 28.8) | 13.4 (5.9 to 24.2)b |
IgA (g/L) | 2.1 (0.2 to 5.7)aab | 3.3 (1.1 to 6.7)aa | 2.8 (0.9 to 7.4)b |
IgM (g/L) | 0.9 (0.3 to 5.5) | 1.1 (0.3 to 2.6) | 1.1 (0.3 to 7.4) |
lymphocytes (/μl) | 800 (220 to 2160) | 790 (230 to 1910) | 890 (190 to 2310) |
leukocytes (/μl) | 6010 (2640 to 11450) | 5835 (2400 to 14008) | 6195 (2160 to 10700) |
platelets (× 103/μl) | 259 (170 to 451)bb | 238 (68 to 355) | 211 (47 to 325)bb |
CD19 + B lymphocytes (/μl) | 55.6 (2.8 to 365.0) | 31.2 (4.8 to 206.1)c | 103.0 (14.7 to 277.4)c |
- CD27++CD38++ (/μl) | 0.8 (0.0 to 7.4)aaaabb | 7.3 (0.1 to 90.9)aaaa | 2.5 (0.7 to 61.4)bb |
- HLADRhighCD27++CD38++ (/μl) | 0.4 (0.0 to 4.3)aaaabbb | 4.3 (0.1 to 58.6)aaaa | 1.8 (0.5 to 55.1)bbb |
- HLADRlowCD27++CD38++ (/μl) | 0.3 (0.0 to 3.2)aaaa | 2.1 (0.0 to 32.3)aaaa | 1.0 (0.2 to 6.3) |
- CD27+IgD− (/μl) | 4.0 (1.1 to 168.1) | 6.2 (0.9 to 47.2) | 10.2 (3.8 to 52.6) |
- CD27+IgD+ (/μl) | 0.9 (0.1 to 9.0) | 0.8 (0.2 to 4.1)cc | 2.2 (0.4 to 7.7)cc |
- CD27−IgD+CD38+ (/μl) | 26.2 (0.2 to 232.9)a | 3.2 (0.0 to 106.4)acccc | 50.7 (2.5 to 118.3)cccc |
- CD27−IgD− (/μl) | 10.0 (0.9 to 28.8) | 7.0 (1.0 to 38.5) | 14.2 (1.7 to 108.5) |
- CD27−IgD+CD38++ (/μl) | 2.3 (0.0 to 59.1) | 2.4 (0.1 to 82.5) | 4.9 (0.2 to 48.6) |
CD3 + T lymphocytes (/μl) | 463.4 (79.9 to 1562.0) | 469.1 (120.5 to 1263.0) | 616.0 (92.7 to 1675.0) |
CD4+ (/μl) | 317.2 (72.7 to 1142.0) | 254.9 (88.6 to 858.2) | 445.7 (46.6 to 1307.0) |
- CD44+CD62L− (/μl) | 23.4 (2.2 to 178.6) | 26.5 (5.4 to 126.8) | 28.5 (5.2 to 334.5) |
- CD45RA−CD45RO+ (/μl) | 105.5 (15.4 to 514.9) | 120.2 (24.8 to 506.7) | 148.2 (22.9 to 754.8) |
- CD45RA+CD45RO− (/μl) | 144.5 (27.7 to 511.3) | 119.6 (19.9 to 534.7) | 114.9 (19.0 to 633.9) |
CD8+ (/μl) | 112.6 (2.0 to 538.0) | 140.8 (17.2 to 334.6) | 142.6 (20.9 to 618.0) |
- CD44+CD62L− (/μl) | 21.5 (0.3 to 363.8) | 33.4 (4.9 to 227.8) | 15.3 (2.8 to 541.4) |
- CD45RA−CD45RO+ (/μl) | 16.1 (0.3 to 332.2) | 31.5 (5.3 to 142.9) | 24.6 (4.7 to 357.8) |
- CD45RA+CD45RO− (/μl) | 77.1 (1.4 to 485.8) | 80.6 (10.5 to 250.1) | 86.1 (4.9 to 370.5) |
CD4−CD8− (/μl) | 28.0 (2.2 to 97.2) | 23.1 (6.2 to 98.4) | 22.1 (2.9 to 174.2) |
- CD44+CD62L− (/μl) | 5.7 (0.1 to 71.6) | 6.8 (1.5 to 38.3) | 6.3 (1.0 to 166.0) |
- CD45RA−CD45RO+ (/μl) | 9.2 (0.1 to 43.0) | 8.5 (0.5 to 55.8) | 10.9 (0.7 to 68.6) |
- CD45RA+CD45RO− (/μl) | 17.9 (0.7 to 70.2) | 12.7 (5.0 to 44.6) | 13.3 (1.7 to 160.2) |
CD123 + CD11c − HLA-DR high PDCs (/μl) | 1.8 (0.4 to 8.5) | 2.0 (0.4 to 6.2) | 0.8 (0.1 to 20.6) |